Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis.

Autor: Adiels M; Department of Molecular and Clinical Medicine and Wallenberg Laboratory, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Health Metrics Unit, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden., Chapman MJ; Dyslipidemia and Atherosclerosis Research Unit (U939), National Institute for Health and Medical Research (INSERM), Pitié-Salpétrière University Hospital, Paris, France; University of Pierre and Marie Curie- Paris 6, Pitié-Salpétrière University Hospital, Paris, France. Electronic address: john.chapman@upmc.fr., Robillard P; Dyslipidemia and Atherosclerosis Research Unit (U939), National Institute for Health and Medical Research (INSERM), Pitié-Salpétrière University Hospital, Paris, France; University of Pierre and Marie Curie- Paris 6, Pitié-Salpétrière University Hospital, Paris, France., Krempf M; INSERM U915 and Nantes Research Centre in Human Nutrition, Nantes, France., Laville M; CNRH-RA, Hospices Civils de Lyon, Lyon 1 University, Pierre Benite, France; INSERM U1060, CarMEN laboratory, Lyon 1 University, INRA 1235, Oullins, France., Borén J; Department of Molecular and Clinical Medicine and Wallenberg Laboratory, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Jazyk: angličtina
Zdroj: Journal of clinical lipidology [J Clin Lipidol] 2018 May - Jun; Vol. 12 (3), pp. 810-821.e1. Date of Electronic Publication: 2018 Mar 29.
DOI: 10.1016/j.jacl.2018.03.083
Abstrakt: Background: Niacin as an adjunct to statin treatment to reduce cardiovascular risk is questioned.
Objective: To evaluate interrelationships between the effects of niacin on mixed dyslipidemia and a spectrum of metabolic and inflammatory biomarkers.
Methods: Obese, nondiabetic, hypertriglyceridemic males (n = 19) with low high-density lipoprotein-cholesterol levels received extended-release nicotinic acid for 8 weeks. Multiple biomarkers were measured using enzyme-linked immunosorbent assay, enzymatic/absorptiometric, or multiplex biochip assays. Treatment effects were determined for each variable and a differential correlation network created on the basis of univariate correlations between baseline and response to niacin treatment for all pairs of variables.
Results: Extended-release niacin treatment favoured normalization of plasma lipid and apolipoprotein profile. Plasma markers of inflammation, hepatic function, cellular adhesion and proliferation, and macrophage phenotype were attenuated; however, insulin resistance increased. Differential network analysis revealed that changes in triglycerides and high-density lipoprotein-cholesterol were closely linked; equally, niacin mediated reductions in total cholesterol, apolipoprotein B, low-density lipoprotein-cholesterol and lipoprotein(a) clustered together, as did homeostatic model assessment of insulin resistance, insulin, and interleukin-6 levels. Two clusters of inflammatory markers were identified, involving (1) intercellular adhesion molecule 1 and high-sensitive C-reactive protein and (2) soluble tumor necrosis factor receptors; and novel clusters involving matrix metallopeptidase 9 and apolipoprotein E, and adiponectin and cystatin C, respectively, were equally revealed. At lower stringency, lipid and insulin resistance clusters were linked; a C-reactive protein-centered cluster linked reduction in apolipoprotein CIII to intercellular adhesion molecule 1, gamma-glutamyltransferase, soluble tumor necrosis factor receptors, and E-selectin.
Conclusion: A niacin-mediated trend to normalize atherogenic mixed dyslipidemia was intimately linked to attenuation of biomarkers of inflammation, cell adhesion, hepatic dysfunction and cell proliferation, but to enhanced insulin resistance and plasma homocysteine elevation.
(Copyright © 2018 National Lipid Association. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: